GLP-1 Lawsuit 2026: Every Drug Named in the MDL — Ozempic, Wegovy, Mounjaro, Rybelsus, Zepbound & Trulicity Compared
The GLP-1 lawsuits name specific branded drugs from two manufacturers: Novo Nordisk's Ozempic, Wegovy, and Rybelsus (semaglutide) and Eli Lilly's Mounjaro, Zepbound (tirzepatide), and Trulicity (dulaglutide). Some 4,025 cases sit in one federal MDL in Pennsylvania. Here is the complete named list, how the brands relate, and which products are not in the case.
- Federal GLP-1 cases are centralized in MDL No. 3094 in the Eastern District of Pennsylvania, with about 4,025 cases pending as of October 2026.
- Only two manufacturers are defendants: Novo Nordisk (semaglutide brands) and Eli Lilly (tirzepatide and dulaglutide brands).
- A 2023 JAMA study of GLP-1 drugs used for weight loss found hazard ratios of 3.67 for gastroparesis, 4.22 for bowel obstruction, and 9.09 for pancreatitis versus the comparison weight-loss drug.
- In September 2023 the FDA added intestinal blockage (ileus) to the Ozempic label's warnings — one of the very injuries the lawsuits allege was under-disclosed.
- The same molecule appears under several brands: semaglutide is Ozempic, Wegovy, and Rybelsus; tirzepatide is both Mounjaro and Zepbound.
For more on how drug-injury litigation works, the Problem Solved channel explains the process step by step.
One MDL, two manufacturers
A GLP-1 receptor agonist is a drug that mimics a gut hormone involved in blood sugar and appetite; the class became famous first for diabetes and then for weight loss. The injury lawsuits — alleging severe stomach paralysis, intestinal blockages, and related harms that plaintiffs say were not adequately warned about — were centralized in February 2024 as MDL No. 3094 in the Eastern District of Pennsylvania. Despite the number of brand names involved, there are only two defendants: Novo Nordisk and Eli Lilly. Which company made your drug determines which half of the case you are in. The docket's current posture is tracked in our Ozempic lawsuit October 2026 status update.
The Novo Nordisk drugs: Ozempic, Wegovy, Rybelsus
All three are semaglutide; the brand tells you the form and the approved purpose. Ozempic is the weekly injection approved for type 2 diabetes — and the name most claims carry, because off-label weight-loss use was widespread. Wegovy is the higher-dose weekly injection approved for weight management. Rybelsus is the daily tablet — the same molecule in pill form — approved for diabetes. Plaintiffs sue over the molecule and its warnings, so all three brands appear in the MDL; a Rybelsus claim is not weaker merely because it was a pill. Novo's older liraglutide brands, Victoza (diabetes) and Saxenda (weight loss), are within the class the litigation covers as well, though they generate fewer filings.
The Eli Lilly drugs: Mounjaro, Zepbound, Trulicity
Lilly's side of the MDL holds three brands. Mounjaro (tirzepatide, a dual GIP/GLP-1 drug) is the weekly injection approved for diabetes; Zepbound is the identical molecule approved for weight management and sleep apnea. Trulicity (dulaglutide) is Lilly's older weekly diabetes injection. The practical point for claimants: check the actual product name on your pharmacy record, not the name in the headline. Patients frequently say 'Ozempic' generically for any of these drugs, and a claim filed against the wrong manufacturer on a mistaken identity wastes months. Pharmacy dispensing records — which your lawyer will pull — state the exact drug, dose, and dates.
The injuries claimed, drug by drug
The MDL's core allegations are gastrointestinal: gastroparesis (stomach paralysis), ileus and intestinal obstruction, severe vomiting requiring hospitalization, and gallbladder disease; the 2023 JAMA figures above are the plaintiffs' favorite citation. The evidence base differs somewhat by drug and by injury, and the science fight is mapped in our GLP-1 gastroparesis lawsuit analysis, while the blockage claims get their own treatment in the Ozempic ileus lawsuit guide. Vision-loss claims alleging NAION — a rare optic-nerve injury — have largely proceeded on a separate track from MDL 3094, so a vision case is evaluated differently from a gastroparesis case even for the same drug.
What is not in the lawsuit: compounded GLP-1s
Compounded semaglutide and tirzepatide — the pharmacy-mixed versions sold by telehealth clinics and med spas during the shortage years — are not products of Novo Nordisk or Eli Lilly, and claims about them do not belong to this MDL. That does not mean an injury on a compounded product is legally worthless; it means it raises different questions (who compounded it, what was actually in it, what warnings were given) outside the branded-drug litigation. If your records show a brand name, you are in the MDL's world; if they show a compounding pharmacy, tell your lawyer exactly that — the distinction changes the whole strategy.
Finding your drug in the paperwork
Start with the pharmacy: dispensing records list the exact brand, dose, and fill dates, and insurers retain the same data on claims histories. Prescriber records add the indication. With those two documents, matching a patient to a named drug takes minutes. The remaining questions are the injury (diagnosed gastroparesis, obstruction, or another claimed harm, documented in hospital or specialist records) and timing (use before the injury, within your state's deadline from when you knew or should have known of the connection). Bring the drug name right, and the rest of the evaluation is the same rigorous screen applied to every mass-tort claim.
Who Benefits From This — and Who Does Not
This named-drug guide is most useful to readers who can match their pharmacy record to one of the two manufacturers' brands, because the MDL is organized by molecule and maker, not by the name patients use casually.
Who benefits:
- Users of named brands with gastrointestinal injuries: How: check the pharmacy record for the exact drug, dose and dates — semaglutide brands Ozempic, Wegovy and Rybelsus; tirzepatide brands Mounjaro and Zepbound; dulaglutide brand Trulicity.
- Rybelsus tablet users: How: the tablet is the same semaglutide molecule, so a tablet claim is not weaker merely because it was a pill.
- Readers who say “Ozempic” for any GLP-1 drug: How: confirm the actual product name first — a claim filed against the wrong manufacturer on a mistaken identity wastes months.
Who benefits less, or not at all:
- Compounded semaglutide users from telehealth clinics: Not in this MDL — compounded products are not made by the defendant manufacturers and need their own evaluation.
- NAION vision-loss claimants: Vision claims have largely proceeded on a separate track from MDL 3094.
- Readers who cannot yet identify their exact product: Benefit less until the pharmacy record names the drug and maker.
Read more: our GLP-1 gastroparesis lawsuit analysis
Frequently asked questions
Is my GLP-1 drug part of the lawsuit?
If it is a branded product from Novo Nordisk (Ozempic, Wegovy, Rybelsus, Victoza, Saxenda) or Eli Lilly (Mounjaro, Zepbound, Trulicity), it is within the class of drugs the MDL covers. Compounded versions are not part of the MDL. Your pharmacy dispensing record gives the definitive product name.
Are Mounjaro and Zepbound treated as different drugs in the case?
They are the same molecule (tirzepatide) sold under two names for different approved uses, and both are named. The same is true of Ozempic, Wegovy, and Rybelsus, which are all semaglutide. Claims are organized by molecule and manufacturer more than by brand.
Which injuries does the GLP-1 lawsuit cover?
The core claims are gastroparesis, ileus and intestinal obstruction, severe persistent vomiting, and gallbladder disease requiring surgery. Vision-loss (NAION) claims have largely proceeded on a separate track from the main MDL and are evaluated under different criteria.
I took a compounded semaglutide from a telehealth clinic. Do I have a claim in the MDL?
Not in this MDL — compounded products are not made by the defendant manufacturers. An injury on a compounded product raises different legal questions about the compounding pharmacy and prescriber, and it needs its own evaluation rather than an MDL filing.
What proof connects me to a named drug?
Pharmacy dispensing records showing the exact brand, dose, and dates, plus prescriber and insurer records. For the injury side, hospital, emergency, or gastroenterology records documenting the diagnosis — for example a gastric-emptying study for gastroparesis — complete the file.
Who benefits most from this named-drug guide — and who should look elsewhere?
Users of the named Novo Nordisk or Eli Lilly brands with gastroparesis, ileus, severe vomiting or gallbladder disease benefit most, once the pharmacy record confirms the exact product. Compounded-product users are not in this MDL and need a separate evaluation, and NAION vision-loss claims run on a separate track.
This article provides general information about the lawsuits and claims described above. It is not legal, financial, or medical advice. For advice about your situation, consult a qualified attorney or medical professional.